Ra Pharmaceuticals Inc. (Nasdaq: RARX) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO
October 27 2016 - 6:00AM
What: Ra Pharmaceuticals
Inc. (Nasdaq:RARX), a clinical stage biopharmaceutical company
focusing on the development of next-generation therapeutics for
diseases of complement dysregulation, will visit the Nasdaq
MarketSite in Times Square in celebration of its initial public
offering (IPO).
In honor of the occasion, Douglas Treco,
Ph.D., Chief Executive Officer and Co-Founder, will ring
the Opening Bell.
Where: Nasdaq MarketSite – 4
Times Square – 43rd & Broadway – Broadcast Studio
When: Thursday, October 27,
2016 – 9:15 a.m. to 9:30 a.m. ET
Ra Pharmaceuticals Media
Contact: Eliza Schleifstein (917)
763-8106 eliza@argotpartners.com
Nasdaq MarketSite: Emily Pan
(646) 441-5120 emily.pan@nasdaq.com
Feed Information: Fiber Line
(Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811
Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media: For multimedia
features such as exclusive content, photo postings, status updates
and video of bell ceremonies, please visit our Facebook
page: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit
our Instagram page: http://instagram.com/nasdaq
For livestream of ceremonies and events, please
visit our YouTube page: http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page: http://twitter.com/nasdaq
For exciting viral content and ceremony photos,
please visit our Tumblr page: http://nasdaq.tumblr.com/
Webcast: A live stream of the
Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or
http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution
photograph of the Market Open, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market open of your choice.
About Ra Pharmaceuticals Ra
Pharmaceuticals is a clinical stage biopharmaceutical company
focusing on the development of nextgeneration therapeutics for
diseases of complement dysregulation and for orphan indications.
The Company utilizes small molecules and peptide approaches to
address pathological targets in the complement cascade. Derived
from its proprietary Extreme Diversity™ peptide chemistry platform,
RA101495 is a macrocyclic peptide inhibitor of complement C5, and
is currently in Phase 1 development for the treatment of paroxysmal
nocturnal hemoglobinuria (PNH). For more information, please visit:
www.rapharma.com.
About Nasdaq Nasdaq
(Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange
technology, listing, information and public company services across
six continents. Through its diverse portfolio of solutions, Nasdaq
enables customers to plan, optimize and execute their business
vision with confidence, using proven technologies that provide
transparency and insight for navigating today's global capital
markets. As the creator of the world's first electronic stock
market, its technology powers more than 70 marketplaces in 50
countries, and 1 in 10 of the world's securities transactions.
Nasdaq is home to more than 3,700 listed companies with a market
value of approximately $9.3 trillion and nearly 18,000 corporate
clients. To learn more, visit: nasdaq.com/ambition or
business.nasdaq.com.
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Sep 2023 to Sep 2024